Metabolite Identification Studies
We can determine the metabolic fate of your molecule or study its activity in cell based systems. Working in collaborative teams, our knowledge base draws from biotransformation specialists alongside biochemists and synthetic/analytical chemists. Our analytical capabilities include high resolution mass spectrometry, NMR and 96 well plate spectrophotometric technology. Both radiolabelled and non-radiolabelled samples are equally accommodated.
The FDA guidance for Safety Testing of Drug Metabolites recommends that the structure of any metabolite which may represent more than 10 % of the exposure in humans should be formally elucidated. The earlier a disproportionate metabolite is recognized and characterised in the drug development process, the lower the risk of downstream delays with better planning of clinical studies.
The expertise and experience, in conjunction with state-of-the-art technology, are available within Arcinova to advise on the optimal approaches for completion of metabolite isolation and identification. Where possible, isolation can be circumvented by hyphenated technologies. The in-house mass spectrometry – Nuclear Magnetic Resonance platform not only enables identification of metabolites, but it permits quantification within a biological matrix.
Bio SpainBioSpain 2018 will be attended by Nathalie Huther, Business Development Manager Europe.
Bio SpainDates: 25th - 27th SeptemberLocation: Seville, Spain
BioForwardThe BioForward event will be attended by Nathalie Huther, Business Development Manager Europe.
BioForwardDates: 4th OctoberLocation: Birmingham, UK
CPhI WorldwideCPhI Worldwide will be attended by Nathalie Huther, Business Development Manager Europe. Nathalie will be located at the DIT stand: 9J40
CPhI WorldwideDates: 9th - 11th OctoberLocation: Madrid, Spain